Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Other Non-Current Liabilities (2016 - 2025)

Neurocrine Biosciences' Other Non-Current Liabilities history spans 16 years, with the latest figure at $219.7 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 32.19% year-over-year to $219.7 million; the TTM value through Dec 2025 reached $219.7 million, up 32.19%, while the annual FY2025 figure was $219.7 million, 32.19% up from the prior year.
  • Other Non-Current Liabilities reached $219.7 million in Q4 2025 per NBIX's latest filing, up from $195.7 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $219.7 million in Q4 2025 to a low of $8.3 million in Q3 2021.
  • Average Other Non-Current Liabilities over 5 years is $92.8 million, with a median of $78.6 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: decreased 7.51% in 2022, then surged 301.17% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $12.3 million in 2021, then surged by 141.46% to $29.7 million in 2022, then skyrocketed by 257.91% to $106.3 million in 2023, then skyrocketed by 56.35% to $166.2 million in 2024, then surged by 32.19% to $219.7 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Other Non-Current Liabilities are $219.7 million (Q4 2025), $195.7 million (Q3 2025), and $210.1 million (Q2 2025).